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Objective. To investigate 1) the signal transduction pathways affected by heat shock protein
27 (HSP27) expression; and 2) the expression and regulation of HSP27 in acute myeloid
leukemia (AML).
Materials and Methods. RNA interference studies for HSP27 in leukemic TF-1 cells were used
to investigate the effectson downstream signal transductionand apoptosis afterVP-16 and CD95/
Fas treatment. HSP27 expression and activation was investigated in AML blasts through
Western blot analysis.
Results. RNA interference for HSP27 resulted in a twofold increase in VP-16-induced apoptosis,
which was preceded by enhanced p38 and c-Jun phosphorylation and a twofold increased
cytochrome c release into the cytoplasm. DAXX co-immunoprecipitated with HSP27, suggesting
an inhibitory role of HSP27 in VP-16-mediated activation of the ASK1/p38/JNK pathway.
CD95/Fas-induced apoptosis, however, was unaffected by HSP27 siRNA, due to upregulation
of HSP27. Although HSP27 was highly expressed and phosphorylated in primitive monocytic
AML blasts (M4-M5, 91%, n 11) and undetectable in myeloid blasts (M1-M2, n  5), VP-
16-mediated apoptosis correlated moderately with HSP27 expression. This is likely due to the
co-expression of p21Waf1/Cip1, which is in the majority of the monocytic AML M4-M5 blasts
constitutively localized in the cytoplasm. Overexpression of cytoplasmic p21 inhibited the
enhanced p38 phosphorylation after HSP27 RNAi, suggesting a predominant anti-apoptotic
role of p21 over HSP27.
Conclusion. 1) HSP27 inhibits VP-16-mediated phosphorylation of p38 and c-Jun, cytochrome
c release, and subsequent apoptosis; 2) HSP27 is expressed and activated in monocytic AML
blasts; 3) cytoplasmic expression of p21 compensates for the lack of HSP27.  2005
International Society for Experimental Hematology. Published by Elsevier Inc.Introduction
Acute myeloid leukemia (AML) is characterized by an accu-
mulation of immature cells in the bone marrow, resulting in
the disruption of normal hematopoiesis [1–3]. The leukemic
population possesses a growth advantage that is in part linked
to the constitutive activation of intracellular proteins that
trigger the activation of anti-apoptotic proteins [4–7]. The
small heat shock protein 27 (HSP27) is a member of the heat
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016/ j .exphem.2005.03.009shock protein (Hsp) family, whose expression is transiently
induced in response to stress. It has been demonstrated that
HSP27 levels change during cellular stress [8] and differenti-
ation [9–11], both on the transcriptional and posttranslational
level [8]. In normal cells, HSP27 mainly exists in large
oligomeric units up to 800 kDa in size. Stress leads to changes
in the multimeric status of the protein due to phosphorylation
of HSP27 on three serine residues [12] that can change the
activity of the protein [13]. HSP27, besides being involved
in cytoskeletal stability, cell motility, and its function as a
chaperone [8,13–15], has been implicated in apoptosis
[11,16–20].
Induction of apoptosis can occur via an intrinsic as well
as an extrinsic signal transduction pathway. The classicalExperimental Hematology. Published by Elsevier Inc.
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chrome c from mitochondria. Cytochrome c interacts with
apoptosis protease activating factor-1 (Apaf-1), which oligo-
merises and binds to pro-caspase-9 [12]. The formation of
this caspase-activating complex, termed the apoptosome,
results in the activation of caspase-9, which in turn triggers
the proteolytic cleavage of pro-caspase-3, leading to
apoptosis [12].
Binding of ligands to death receptors on the cell surface
(e.g., CD95/Fas) not only results in the formation of the death-
inducing signaling complex (DISC) via the recruitment of
the adapter molecule FADD, but also to the recruitment
of DAXX to the cytosolic end of the CD95/Fas receptor
[21,22]. DAXX then binds apoptosis signal regulating
kinase-1 (ASK1), which in turn activates c-Jun N-terminal
kinase (JNK) and p38, leading to cytochrome c release and
activation of caspases [16,17,23,24].
The mode of HSP27 action in apoptosis is still unclear
but could exert its effect at the level of mitochondrial stability
[19,25] or DAXX signaling [16,17].
Since HSP27 expression has been observed in multiple
malignancies [26,27] including AML [28,29] and HSP27
expression is frequently correlated with unfavorable progno-
sis [30], we questioned whether HSP27 plays an important
role in the protection of AML blasts against CD95/Fas-
or VP-16-induced apoptosis; both have been described to
activate the DAXX pathway [7,16,17].
Here we demonstrate that HSP27 is predominantly ex-
pressed and phosphorylated in AML blasts of the monocytic
lineage. RNA interference indicates that HSP27 affects the
VP-16-induced DAXX pathway through the modulation of
JNK and p38 [7,12] activation, resulting in the enhanced
cytochrome c release and induction of apoptosis. Addition-
ally, our results also indicate that in monocytic leukemia,
HSP27 is not the determining anti-apoptotic factor, since
cytoplasmic localized p21Waf1/Cip1 is able to reverse the en-
hanced VP-16-induced phosphorylation of p38 after RNAi
for HSP27.
Experimental procedures
Patient population and isolation of AML cells
Peripheral blood cells or bone marrow cells from 16 adult
untreated patients with AML were studied after informed
consent. The AML cases were defined according to the
classification of the French-American-British (FAB) com-
mittee as M0-M6 [31]. AML blasts were isolated by density-
gradient centrifugation. The cells were cryopreserved in
aliquots of 20 to 30 × 106 cells in RPMI 1640 (Biowhittaker,
Verviers, Belgium) supplemented with 10% dimethylsulfox-
ide (DMSO; Sigma, St. Louis, MO, USA) and 10% fetal
bovine serum (FBS; Bodinco, Alkmaar, The Netherlands),
employing a method of controlled freezing and storage in
liquid nitrogen. After thawing, T lymphocytes were depletedby 2-aminoethylisothioronium bromide (AET)-treated sheep
red blood cell (SRBC) rosetting. The cell population con-
sisted of more than 98% AML blasts as determined by May-
Gru¨nwald-Giemsa staining. Fluorescence-activated cell
sorting (FACS) analysis demonstrated less than 1% CD3
(Becton-Dickinson, Sunnyvale, CA, USA)-positive cells.
Preparation of monocytes,
granulocytes, and CD34 BM cells
Peripheral blood cells were obtained from healthy volunteer
blood donors, and mononuclear cell suspensions were pre-
pared by Ficoll-Hypaque density-gradient centrifugation.
T lymphocytes were depleted by AET-treated SRBC rosett-
ing. Monocytes were further enriched by plastic adherence
(1 hour, 37C, 5% CO2) and demonstrated a purity greater
than 95% detected by FACS analysis with anti-CD14 anti-
body (Becton-Dickinson, Sunnyvale, CA, USA).
Peripheral blood from healthy volunteers, anti-coagulated
with 0.32% sodium citrate, was used to isolate granulocytes
as described by Fuhler et al. (and references therein) [32].
CD34 cells were isolated from bone marrow from
healthy donors by first making mononuclear cell suspensions
followed by incubation of the suspension with phycoer-
ythrin-labeled anti-CD34 antibody for 30 minutes at 4C
and subsequent FACS sorting using the MoFlo (DakoCyto-
mation, Carpinteria, CA, USA). CD34/CD36 and CD34/
CD36 cell populations were obtained by incubating the
AML blasts with phycoerythrin-labeled anti-CD34 and
FITC-labeled anti-CD36 antibodies for 30 minutes at 4C.
Subsequently, the different cell populations were isolated by
FACS sorting using the MoFlo.
Cell culture, viral vectors, and transfections
AML blasts were cultured at 37C, 5% CO2 at a density of
1 × 106/mL in RPMI 1640 media supplemented with 100 U/
mL penicillin, 100 µg/mL streptomycin (ICN Biomedicals,
Aurora, OH, USA), and 10%FBS. Isolated CD34cells were
cultured in IMDM medium (ICN Biomedicals) sup-
plemented with 10% FBS, 100 U/mL penicillin, 100 µg/mL
streptomycin. Monocytes were cultured at 37C, 5% CO2 at
density of 1 × 106/mL in RPMI 1640 and 10% FBS. The
human cell lines U937 (ATCC, Manassas, VA, USA, Product
No. CRL-1593.2), THP-1 (ATCC, Product No. TIB-202),
and HL-60 (ATCC, Product No. CCL-240) were cultured
in RPMI 1640 supplemented with 10% FBS. The human
cell line TF-1 (ATCC, Product No. CRL-2003) was cultured
in RPMI 1640 supplemented with 10% FBS and 10 ng/mL
GM-CSF (Genetics Institute, Cambridge, MA, USA).
pMSCV-p21dNLS was constructed by removing the C-
terminal bipartite nuclear localization signal (NLS; RKRR,
Amino acids 140–143) via polymerase chain reaction (PCR)
from pCMV-p21 (kindly provided by Prof. Dr. R.H. Medema
and Dr. P. Coffer) and ligating the XhoI-EcoRI fragment
into pMSCV-iGFP (kindly provided by Dr. J.J. Schuringa).
TF-1 cells were transduced with viral particles collected from
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p21dNLS using FuGENE6 (Roche, Almere, The Nether-
lands). GFP TF-1 cells were isolated by FACS sorting
using the MoFlo.
Reagents and antibodies
An antibody against phosphorylated p38 was obtained from
New England Biolabs (Beverly, MA, USA). Antibody
against HSP27 was purchased from Stressgen (Victoria, BC,
Canada); anti-actin (C4) was obtained from ICN Biomedi-
cals (Aurora, OH, USA). Antibodies against c-Jun, cyto-
chrome c, and GAPDH were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA), pan-serine from
Zymed Laboratories (San Francisco, CA, USA). Anti-FLAG
(M2) was obtained from Sigma. Antibody against p21 was
bought from Transduction Laboratories (Lexington, KY,
USA). Anti-CD34-HPCA2-PE was obtained from Becton-
Dickinson. And CD36 FITC was obtained from IQ Products
(Groningen, The Netherlands). Recombinant human (Rh)
interleukin (IL)-1β was obtained from Mekesson HBOC
Bioservices (Rockville, MD, USA). Rh granulocyte-mono-
cyte colony-stimulating factor (GM-CSF) were purchased
from Genetics Institute (Cambridge, MA, USA). The VP-
16 was obtained from TEVA (Haarlem, The Netherlands)
and the apoptosis-inducing monoclonal antibody CD95/Fas
(7C11) was obtained from Immunotech (Marseille, France).
Preparation of protein extracts and Western blotting
The amount of HSP27, GAPDH, p21Waf1/Cip1, and actin and
the degree of phosphorylated p38, c-Jun, and pan-serine
were determined by SDS-PAGE analysis (sodium dodecyl
sulfate–polyacrylamide gel electrophoresis) on whole-cell
extracts. Cells were harvested and total cell extracts were
prepared by resuspending the cells in lysis buffer (20 mM
Tris HCl pH 7.6, 100 mM NaCl, 10 mM EDTA, 1% NP-
40, 10% glycerol, 2 mM Na3VO4, 2 mM PMSF, 1 µM
pepstatin, and 1 mM DTT) and kept for 15 minutes on
ice. Binding of each antibody was detected by HRP-labeled
secondary antibodies using enhanced chemiluminesence
(ECL) according to the manufacturer’s recommendations
(Amersham Life Sciences, Buckinghamshire, UK).
For cytoplasmic and nuclear extracts, cells were harvested
and were prepared according to the “mini extracts”
method [33]. The extracts were normalized for protein con-
tent prior to SDS-PAGE. Proper fractionation and lack of
leakage of nuclear proteins to the cytosol was determined by
Western blotting for the nuclear protein retinoblastoma (Rb).
RNA interference
Short interfering RNA (siRNA) duplexes for HSP27 were
made using the Silencer siRNA construction kit from
Ambion (Austin, TX, USA) according to the manufacturer’s
protocol. The HSP27 target sequence used is: AAGCTG-
CAAAATCCGATGAGA. GAPDH control siRNA duplexes
are provided within the kit. Two × 106 TF-1 cells were
transfected with a final concentration of 25 nM of RNAiduplexes using oligofectamine according to the manufactur-
er’s protocol (Invitrogen, Breda, The Netherlands). Lysates
were prepared at the indicated time points in lysis buffer
and equal amounts of protein were subjected to Western
blot analysis.
Combined annexin V/PI staining procedure
Viability was assessed using an annexin V staining kit (IQ
Products, Groningen, The Netherlands) according to the
manufacturer’s recommendations. Briefly, after 6 hours of
culture in RPMI 1640 medium supplemented with 10% FBS,
with or without addition of VP-16 (20 µg/mL) or CD95/Fas
(2 µg/mL), cells were harvested, resuspended in 100 µL
calcium buffer containing 5 µL of annexin V, and incubated
for 20 minutes at 4C in the dark. Cells were washed with
5 mL calcium buffer and subsequently incubated in 300 µL
calcium buffer containing 2.5 µL of propidium iodide (PI) for
10 minutes in the dark at 4C. Finally, binding of fluorescein-
conjugated annexin V and PI was measured by fluorescence-
activated cell sorting.
Immunoprecipitation
A total of 107 AML blasts were cultured for 16 hours in
RPMI 1640 medium supplemented with 10% FBS. Cells
were harvested, washed with ice-cold phosphate-buffered
saline (PBS) containing 1 mM sodium orthovanadate, and
subsequently lysed in 500 µL lysis buffer (20 mM Tris HCl
pH 7.6, 100 mM NaCl, 10 mM EDTA, 1% NP-40, 10%
glycerol, 2 mM Na3VO4, 2 mM PMSF, 1 µM pepstatin, and
1 mM DTT) for 15 minutes on ice. Cell lysates were
clarified at 10,000g for 20 minutes and incubated with 5 µL
HSP27 antibody. After 4 hours rotating, protein A sepharose
beads were added and incubated overnight at 4C. Immuno-
complexes were washed 3 times with lysis buffer and sepa-
rated by SDS-PAGE. Binding of anti-pan-serine antibody
was detected using ECL (Amersham, UK).
Twenty × 106 TF-1 cells were electroporated with 20
µg of pCDNA3 MYC-FLAG-DAXX and 20 µg of pCDNA3
HA-ASK1 at 240 V and 960 µF. After 24 hours cells were
harvested, and co-immunoprecipitations were performed
as described above. Binding of anti-FLAG antibody was
detected using ECL.
Cytochrome c ELISA
The Quantikine human cytochrome c immunoassay from
R&D Systems (Minneapolis, MN, USA) was used to mea-
sure cytochrome c levels in the cytoplasm in response to VP-
16 or CD95/Fas treatment, according to the manufacturer’s
recommendations. Cytoplasmic and mitochondrial frac-
tions were separated using the mitochondria isolation kit
from Sigma (Zwijndrecht, The Netherlands).
Statistical analysis
The Student’s t-test for paired samples was used to determine
statistical significance of the data about apoptosis induction
in the TF-1 cell line. The 2 × 2 contingency test was
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and HSP27 expression.
Results
HSP27 expression in hematopoietic cells
To determine whether HSP27 is expressed in different hema-
topoietic cells, we isolated granulocytes, monocytes, mono-
nuclear bone marrow cells, and CD34 cells from healthy
donors. Mononuclear cells from different donors express
HSP27 at equal levels, as well as monocytic cells and CD34
cells (Fig. 1A). In terminally differentiated granulocytes,
however, HSP27 could not be detected. A differentiation-
dependent expression was also observed in cell lines. HSP27
was highly expressed in the monocytic cell lines THP-1 and
U937; moderate expression was observed in the erythroleu-
kemic cell line TF-1; and in the myeloid cell line HL-60
HSP27 could not be detected (Fig. 1B).
RNA interference for HSP27
enhances apoptosis after VP-16 treatment
To investigate whether HSP27 plays a role in the apoptotic
process in leukemic cells, RNA interference was used to
knock down HSP27 protein levels in TF-1 cells. Figure 2A
shows the decrease in HSP27 levels after transfection with
Figure 1. Expression of HSP27 in normal hematopoietic cells and cell
lines. (A): Bone marrow mononuclear cells, granulocytes, and monocytic
cells from healthy donors were isolated and cultured as described in materi-
als and methods. CD34 cells were isolated from bone marrow from healthy
donors by making mononuclear cell suspensions followed by incubation
of the suspension with phycoerythrin-labeled anti-CD34 antibody for 30
minutes at 4C and subsequent FACS sorting using the MoFlo. HSP27
expression was investigated by Western blot analysis. Actin is shown as
loading control. A representative experiment is shown. (B): HL-60, THP-
1, U937, and TF-1 cells were cultured as described in the materials and
methods section, and lysates were analyzed for HSP27 expression using
Western blot analysis. Actin is shown as loading control. A representative
experiment is shown.Figure 2. RNA interference for HSP27 specifically knocks down HSP27
expression and enhances VP-16-induced apoptosis. (A): 2 × 106 TF-1 cells
were transfected using oligofectamine with RNA duplexes targeting HSP27,
as described in materials and methods. On the indicated time points, lysates
were made and subjected to Western blot analysis for HSP27 expression.
Actin is shown as loading control. A representative example of 5 experi-
ments is shown. (B): To indicate specificity, TF-1 cells were also transfected
with RNA duplexes targeting GAPDH. Western blot analysis on day 4
indicates that both RNA duplexes are specific. A representative example
of 5 experiments is shown. (C): 4 days after transfection with either HSP27
RNAi or control GAPDH RNAi, TF-1 cells were treated with VP-16
(20 µg/mL) or CD95/Fas (2 µg/mL) for 6 hours. Apoptosis was measured
with annexin V/PI staining using flow cytometry as described in materials
and methods. A representative example of 5 independent experiments
performed in triplicate is shown. (*  p  0.005).
siRNAs in time. After two days HSP27 levels were reduced
approximately 50% compared to the expression levels in
untransfected cells (-). A further reduction in HSP27 pro-
tein levels was observed 3, 4, and 5 days after RNAi transfec-
tion. The siRNAs used were specific, since no effect on
GAPDH expression was observed using HSP27 siRNAs and
vice versa (Fig. 2B).
To investigate whether HSP27 indeed protects against
apoptosis, TF-1 cells were transfected with either HSP27 or
GAPDH siRNAs and the percentage of apoptotic cells was
determined by means of annexin V/PI staining followed by
flow cytometry, 6 hours after incubation with VP-16 or
CD95/Fas. VP-16-mediated apoptosis was significantly in-
creased in HSP27-RNAi-treated cells compared with the
control GAPDH-RNAi-treated cells (26.8% ± 8.7% vs
5.8% ± 3.8%, n 5, p  0.005, Fig. 2C). HSP27 does not
seem to be involved in CD95/Fas-induced apoptosis, since
knockdown of HSP27 did not significantly affect the per-
centage of apoptotic cells upon treatment with CD95/Fas.
RNA interference for HSP27 enhances cytochrome
c release from the mitochondria in response to VP-16
Next we investigated at which level HSP27 affected the VP-
16-induced apoptotic response. HSP27 has been described
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ultimately preventing the activation of pro-caspase-3 by
caspase-9-mediated proteolysis. Co-immunoprecipitation
studies could not detect complex formation between HSP27
and either pro-caspase-3 or cytochrome c in TF-1 cells,
which corresponds with observed cleavage of pro-caspase-
3 after CD95/Fas treatment (data not shown).
Next we investigated whether HSP27-blocked cyto-
chrome c release from mitochondria [34]. To investigate
whether HSP27 inhibits the release of cytochrome c upon
VP-16 and CD95/Fas treatment, we performed ELISAs
(enzyme-linked immunosorbent assays) on cytosolic ex-
tracts from VP-16 and CD95/Fas-treated cells. Control
GAPDH siRNA-treated cells showed a twofold increase in
cytochrome c release upon VP-16 treatment (Fig. 3A) and
a 1.5-fold increase was found after CD95/Fas treatment.
Knockdown of HSP27 resulted in a fourfold increase in
cytochrome c release upon VP-16 treatment, whereas the
effect of CD95/Fas was not altered (Fig. 3A). These results
indicate that HSP27 interferes with VP-16-induced cyto-
chrome c release from mitochondria.
RNA interference for HSP27 influences
phosphorylation of p38 and c-Jun after VP-16 treatment
Cytochrome c release from mitochondria has been shown
to be involved in JNK-mediated, c-Jun-mediated cell death
[24,35]. Therefore we focused on the downstream effectors ofVP-16- and CD95/Fas-induced apoptosis, i.e., the stress-
activated protein kinase (SAPK, also known as JNK;
c-Jun amino-terminal kinase) and the p38 MAP kinase [23].
TF-1 cells transfected with either HSP27 or GAPDH
siRNAs were treated with VP-16 or CD95/Fas for 1 and 3
hours. P38 and c-Jun activation were determined using West-
ern blot analysis (Fig. 3B). VP-16 induced a strong activation
of p38 and c-Jun in the GAPDH RNAi transfected TF-1
cells after 3 hours, whereas no activation was observed using
CD95/Fas (lanes 2 and 3). RNA interference for HSP27
further increased VP-16-induced p38 phosphorylation levels
approximately threefold (compare Fig. 3B lanes 5 and 10).
In addition, the kinetics of p38 phosphorylation were also
changed, since phosphorylation of p38 was already observed
after 1 hour of VP-16 treatment in HSP27 RNAi-treated cells
(compare lanes 4 and 9). A similar effect was found on c-
Jun phosphorylation after 3 hours of VP-16 treatment.
In accordance with the absence of enhanced apoptosis,
CD95/Fas had no effect on p38 and c-Jun phosphorylation,
although JNK has been reported to be a downstream target
of CD95/Fas-induced apoptosis by caspase-independent
pathways [17]. This coincided with an upregulation of
HSP27 expression after CD95/Fas treatment that was not
only observed in the control cells, but also in the HSP27
RNAi transfected cells, despite the presence of the siRNA
(Fig. 3B, compare lanes 1, 2, and 3 to 6, 7, and 8 respec-
tively). In nontransfected HL-60 cells CD95/Fas treatmentFigure 3. RNA interference for HSP27 enhances the release of cytochrome c and modulates the phosphorylation of p38 and c-Jun in response to VP-16. (A):
4 days after transfection with either HSP27 RNAi or control GAPDH RNAi, TF-1 cells were treated with VP-16 (20 µg/mL) or CD95/Fas (2 µg/mL) for
the indicated hours and cytochrome c release was measured in cytoplasmic extracts by ELISA, as described in materials and methods. Relative values
normalized against untreated cells are shown. A representative case of three individual experiments is shown. (B): 4 days after transfection with either
HSP27 RNAi or control GAPDH RNAi, TF-1 cells were treated with VP-16 (20 µg/mL) or CD95/Fas (2 µg/mL) for 1 or 3 hours and subjected to Western
blot analysis for phosphorylated p38, c-Jun, and HSP27. Actin is shown as loading control. A representative example is shown. (C): 20 × 106 TF-1 cells
were electroporated with 20 µg of pCDNA3 MYC-FLAG-DAXX with or without 20 µg of pCDNA3 HA-ASK1. After 24 hours cells were lysed in 500
µL lysis buffer. By immunoprecipitation (IP) of HSP27 and Western blot analysis for anti-FLAG, complex formation between HSP27 and DAXX was
investigated. Immunocomplexes were detected using ECL. A representative example is shown.
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sion, these data demonstrate that knockdown of HSP27 leads
to an enhanced activation of p38 and c-Jun in response to VP-
16, indicating a role for HSP27 upstream from mitochondria.
HSP27 forms a complex with
DAXX in an ASK-1-dependent manner
Since HSP27 has been described to interact with DAXX
[16,17], which is located upstream of ASK1, an activator of
p38 and JNK [36,37], we performed co-immunoprecipitation
studies to investigate whether HSP27 interacts with DAXX.
TF1 cells were transfected with FLAG-DAXX and ASK1
expression plasmids as indicated. In Figure 3C, we show
that complex formation between DAXX and HSP27 occurs
and that this is ASK1 dependent (Fig. 3B, panel IP). In
the absence of ASK1, FLAG-DAXX could not be detected
in the precipitates (lanes 1 and 2). Co-expression of both
ASK1 and DAXX led to massive cell death (data not shown),
resulting in lower amounts of protein in the ASK1/DAXX
transfected samples (totals, lanes 3 and 4).
Summarizing, these data indicate complex formation
between HSP27 and DAXX in TF-1 cells and suggest a
protective effect of HSP27 against VP-16-induced DAXX/
JNK/p38 activation.
HSP27 expression in acute myeloid leukemia
In the erythroleukemic cell line TF-1 we demonstrated that
knockdown of HSP27 enhances VP-16-mediated apoptosis
via modulation of p38 and c-Jun phosphorylation and subse-
quent mitochondrial cytochrome c release, which eventually
results in enhanced apoptosis.
Therefore we questioned whether HSP27 also protects
AML blasts against an apoptotic insult. In view of the high
expression of HSP27 in CD34 and monocytic cells (Fig.
1A), we first studied HSP27 expression levels in myeloid
(FAB M1/M2, n 5) and monocytic (FAB M4/M5, n 11)
AML samples. None of the AML M1/M2 cases expressed
HSP27, despite the presence of high CD34 antigen levels
in 60% of these cases (Fig. 4 and Table 1). In contrast,
10 out of 11 AML M4/M5 patients demonstrated distinct,
although variable, HSP27 expression (correlation p 0.005;
Fig. 4 and Table 1). Within these AML patients, HSP27 is
most prominently expressed within immature AML progeni-
tors (CD34/CD36) as compared to the more differentiated
AML cells (CD34/CD36), investigated through FACSTable 1. FAB classifications, percentage of apoptotic cells, expression
patterns, and CD34 percentages in patients with AML
AML Apoptosis Apoptosis % CD34
case FAB % VP-16 % Fas HSP27 p21 cells
1 M5 8 16   3
2 M1 n.d.* n.d.* – n.d. 1
3 M1/2 27 14 – – 40
4 M5 9 2   3
5 M4 17 5   n.d.
6 M4 16 21   n.d.
7 M5 16 42 – /  1
8 M4 4 28   5
9 M4 28 2  – 2
10 M2 16 20 – – 8
11 M5 11 12   3
12 M5 8 5   1
13 M1 25 49 – – 91
14 M5A 51 8  – n.d.
15 M1 16 1 – / 80
16 M5 14 3  – 64
TF-1 20 10  –
n.d. not determined, * spontaneous apoptosis 90%, FAB French –
American-British classification, VP-16 percentage of apoptosis induced
by VP-16; Fas  percentage of apoptosis induced by CD95/Fas,
HSP27 HSP27 expression levels; p21 p21waf1/Cip1 expression levels, %
CD34 cells the percentage of CD34 positive cells as determined by
FACS analysis.
sorting and Western blot analysis (n 2, data not shown).
To exclude that experimental procedures modulated HSP27
levels, fresh AML blast and cryopreserved blasts of the
same patient were compared, directly and several hours after
isolation. No effect of cryopreservation and isolation proce-
dures was observed on HSP27 levels (data not shown).
Expression of HSP27 is not correlated
with decreased apoptosis in acute monocytic leukemia
In view of the expression of HSP27 in acute monocytic
leukemia, we questioned whether HSP27 expression was
related to sensitivity towards apoptotic stimuli. Both myeloid
(FAB M1/M2) and monocytic (FAB M4/M5) AML blasts
were incubated with VP-16 or CD95/Fas. After 6 hours of
incubation, the percentage of apoptotic cells was determined
by annexin V/PI staining. In the group without HSP27 ex-
pression more than 15% VP-16-mediated apoptosis was
found in all cases studied, whereas 60% of the HSP27-
expressing cases demonstrated less than 15% apoptosis.Figure 4. HSP27 is differently expressed in AML samples. Acute myeloid leukemic cells were isolated and cultured as described in materials and methods
and HSP27 expression was investigated using Western blot analysis. A representative case of 3 experiments is shown. The 2 × 2 contingency test was used
to determine association between FAB classification and HSP27 expression (correlation, p  0.005).
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lation was observed between VP-16- and CD95/Fas-induced
apoptosis and HSP27 expression levels (Fig. 5A and
Table 1).
Phosphorylation and activation of HSP27
Since no distinct correlation between HSP27 expression and
decreased apoptosis were detected, we wondered whether
HSP27 is phosphorylated and activated in AML cells. To
investigate whether the HSP27 protein detected in the
monocytic AML samples is phosphorylated, immunoprecip-
itations (IP) were performed on AML lysates using an anti-
HSP27 antibody. Following IP, Western blot analysis was
performed with an anti-phosphoserine antibody (Fig. 5B and
C). Figure 5B shows faint phosphorylation of HSP27 in
untreated TF-1 cells (lane 1). In the absence of HSP27
antibodies, HSP27 was not precipitated (lane 2). Interleukin
(IL)-1 treatment, a known activator of HSP27, resulted in a
transient increase in HSP27 serine phosphorylation (lanes 3
and 4) [12,38,39]. The finding of phosphorylated and hence
activated HSP27 in the TF-1 cell line is in accordance with
the finding that it interacts with DAXX in these cells, since
this phosphorylated dimer of HSP27 has been described to
interact with DAXX [17]. Finally, Figure 5C depicts the
results of 6 AML cases. Case 9 shows IL-1-stimulated AML
blasts as a positive control. These results demonstrate that
HSP27 is phosphorylated in all AML cases studied irrespec-
tive of apoptotic sensitivity.
The cyclin-dependent kinase inhibitor
p21Waf1/Cip1 is co-expressed with HSP27
in monocytic AML blasts and can block the
enhanced VP-16-induced apoptosis after HSP27 RNAi
The variability in the results of the sensitivity of monocytic
leukemic cells towards apoptotic stimuli might be related
to other (more dominant) factors that affect the apoptotic
process. As recently described and confirmed in this study
(Table 1, Fig. 6A, similar to Fig. 4B, with Western blot
for p21), monocytic leukemic cells frequently express the
cyclin-dependent kinase inhibitor p21Waf1/Cip1 in the cyto-
plasm, which counteracts the effects of VP-16 on the apop-
totic program [7]. In 70% of the HSP27-expressing AML
cases, p21 was co-expressed, whereas in the AML cases
with no HSP27 expression, p21 was expressed in 40% of
the cases, indicating that at least two proteins are protective
in many monocytic leukemias. We therefore investigated
whether p21 could inhibit the enhanced effect on VP-16-
induced apoptosis after HSP27 RNAi by using Western blot
analysis for phosphorylated p38. TF-1 cells were virally
transduced with an expression construct for cytoplasmic p21
(p21dNLS). This p21dNLS lacks the bipartite nuclear local-
ization signal and is therefore retained in the cytoplasm,
where it has been shown to inhibit apoptosis [7,40,41].
Figure 6B demonstrates cytoplasmic localization of the p21
dNLS protein in TF-1 cells. These cells were transfected
with HSP27 or GAPDH siRNAs and treated with VP-16 forFigure 5. VP-16 and CD95/Fas-mediated apoptosis and HSP27 phosphory-
lation in AML cells. (A): Apoptosis was induced by culturing the AML
cells in the presence of VP-16 (20 µg/mL) or CD95/Fas (2 µg/mL). After
6 hours of culture, binding of fluorescein-conjugated annexin V and PI
was measured by fluorescence-activated cell sorting. The Mann-Whitney
U-test was used to analyze differences in apoptosis between the two groups
of differentially expressing HSP27 AML blasts (presence or absence of
HSP27 expression and M1/M2 vs M4/M5 FAB classification), but no
significant differences could be observed. The dotted line represents the
15% apoptosis level. A representative example of two experiments is shown.
(B): By immunoprecipitation (IP) of HSP27, and Western blot analysis for
pan-serine phosphorylation, the activation of HSP27 was investigated. As
control for the HSP27 IP and phosphorylation analysis, performed in the
AML cases, the procedure was tested in TF-1 cells. The first lane shows
untreated TF-1 cells. Lane 2 shows the IP procedure without antibody,
indicating specific pull-down of HSP27 in the other lanes. Lane 3 shows
TF-1 cells treated for 30 minutes with 10 ng/mL IL-1β and lane 4 shows
90 minutes of treatment with 10 ng/mL IL-1β, indicating the transient
phosphorylation in TF-1 cells. The HSP27 input is shown here as loading
control and this is the HSP27 in total cell lysates before the IP procedure.
A representative example is shown. (C): 107 AML blasts were cultured
for 16 hours in RPMI 1640 medium supplemented with 10% FBS. Cell
lysis and IP of HSP27 is performed as described in materials and methods.
The activation of HSP27 was investigated as described above. Input
indicates HSP27 levels in total lysates before IP. Six representative cases
are shown. In order to show that indeed phospho-HSP27 is detected, AML
case 9 is also treated with 10 ng/mL IL-1β, a known stimulator of HSP26
phosphorylation. Actin is shown as loading control.
H. Schepers et al. /Experimental Hematology 33 (2005) 660–670 667Figure 6. p21 is co-expressed with HSP27 and cytoplasmic p21 (p21dNLS) inhibits enhanced phosphorylation of p38 after RNA interference for HSP27
in response to VP-16. (A): Acute myeloid leukemic cells were isolated and cultured as described in materials and methods. HSP27 (same as Fig. 4A) and
p21 expression was investigated using Western blot analysis. (B): TF-1 cells were virally transduced with pMSCV-p21dNLS and nuclear and cytoplasmic
fractions were isolated as described in materials and methods. Western blot analysis was performed on p21 to demonstrate cytoplasmic localization. Rb is
shown to indicate proper fractionation. Actin is shown as loading control. (C): 4 days after transfection with either HSP27 RNAi or control GAPDH RNAi,
TF-1 mock or TF-1 p21dNLS cells were treated with VP-16 (20 µg/mL) for 3 hours and subjected to Western blot analysis for phosphorylated p38 and
HSP27. Actin is shown as loading control. A representative example is shown.3 hours. Cell lysates were prepared and subjected to Western
blot analysis for the activation of p38. Figure 6C dem-
onstrates that HSP27 siRNAs reduced HSP27 levels in both
mock and p21 infected TF-1 cells and that p38 phosphoryla-
tion is only increased in response to VP-16 treatment in
mock transfected HSP27 siRNA TF-1 cells. (Compare lanes
2 and 4 with 6 and 8). These data suggest that cytoplasmic
p21 can compensate for a lack of HSP27 and block VP-16-
induced apoptosis via the p38 pathway.
Discussion
In this study we investigated the potential mechanisms by
which HSP27 modulates the apoptotic process in AML blast
cells, since co-expression of HSP27 with additional proteins
is linked to an unfavorable prognosis [28,29]. Our results
demonstrate lineage-restricted expression of HSP27 in
normal hematopoietic cells and their malignant counterparts.
Normal CD34 cells and monocytes express high levels of
HSP27, whereas in AML cells, HSP27 expression is predom-
inantly restricted to monocytic leukemia. HSP27 appeared
to be more expressed in more primitive leukemic progenitor
cells, i.e., the CD34/CD36 sorted cell fraction, as has
been demonstrated for other anti-apoptotic proteins [42], un-
derscoring a functional relevance of HSP27 in the malignant
stem cell compartment.However, functional studies with VP-16 did not show a
uniform response pattern in monocytic leukemia with regard
to VP-16-mediated apoptosis, although HSP27 was phos-
phorylated in all AML cases. An explanation for this appar-
ent discrepancy is the expression of additional anti-apoptotic
proteins including p21Waf1/Cip1, which is cytoplasmic local-
ized in monocytic leukemia and interferes with the VP-16-
mediated p38 and c-Jun phosphorylation [7]. Overexpression
of a cytoplasmic form of p21 in the TF-1 cell line reversed
the VP-16-induced effect seen on the activation of p38 after
HSP27 RNAi, indicating that p21 can substitute for HSP27
as an anti-apoptotic factor. Functional studies demonstrate
that HSP27 is an important anti-apoptotic factor in the VP-
16-induced apoptotic process. Both VP-16 and CD95/Fas
can induce apoptosis through the extrinsic signal transduc-
tion pathway [7,12]. Induction of apoptosis through this
pathway involves translocation of the nuclear protein DAXX
to the membrane, where it can bind to the cytosolic end of the
CD95/Fas receptor [43]. Following binding to the CD95/
Fas receptor, DAXX binds to ASK1 [12]. ASK1 activation
in turn leads to activation of the stress-activatedprotein kinase
(SAPK, also known as JNK; c-Jun amino-terminal kinase)
and p38 subgroups of MAP kinases [23,36], which have
also been described to occur upon VP-16 treatment [7].
The results presented here indicate that HSP27 RNA
interference resulted in enhanced phosphorylation of p38
and c-Jun (a target of JNK) in response to VP-16, but not to
H. Schepers et al. /Experimental Hematology 33 (2005) 660–670668CD95/Fas stimulation. In addition, HSP27 RNA interference
resulted in an increased release of cytochrome c to the cyto-
plasm, which has been shown to require ASK1/JNK activa-
tion [24,35,44]. The kinetics of these results suggest that
cytochrome c release is downstream of the DAXX/ASK1/
JNK pathway. c-Jun and p38 phosphorylation are observed
as early as 1 to 3 hours after VP-16 treatment, followed at
5 hours by a release of cytochrome c to the cytoplasm.
The sequential activation rather than parallel activation is
confirmed by experimental evidence that ASK1-mediated
apoptosis can be blocked by the mitochondrial pore opening
inhibitor, cyclosporin A, whereas activation of p38 MAPK/
JNK is left unaltered [45].
Complex formation between HSP27 and DAXX, as con-
firmed here, further underscores a role for HSP27 at the
level of DAXX [16,17]. Since HSP27-DAXX complex for-
mation is ASK1 dependent, it is likely that HSP27 only
interacts with DAXX when it acquires a pro-apoptotic func-
tion. This is consistent with a role for HSP27 in blocking
DAXX translocation to the cytoplasm [17], where it exerts
a pro-apoptotic function rather than a transcriptional regula-
tory function [46].
Bcl-2 family members are known to play a role in mito-
chondrial integrity and cytochrome c release [47]. DAXX/
ASK1 activation has been shown to inactivate the anti-apop-
totic protein bcl-2 [48] and activate pro-apoptotic proteins
such as Bax, Bim, and Bid [49] (and references therein).
HSP27 expression and hence DAXX/ASK1 inactivation
might also influence the balance between pro- vs anti-apop-
totic signals at this level. Since HSP27 and bcl-2 protect
against apoptosis with different efficiencies and different
pathways [50], more work needs to be done to clarify the
similarities and differences in the affected signal transduc-
tion pathways.
A different response pattern was observed with CD95/
Fas. HSP27 levels were strongly upregulated by CD95/Fas in
the studied cases. This elevated level of HSP27 subsequently
prevented the phosphorylation of p38 and c-Jun. Despite
the absence of p38 and c-Jun activation, CD95/Fas did
induce apoptosis in TF-1 cells to some extent, although not
comparable to VP-16-induced levels (Table 1).
It is conceivable that CD95/Fas-induced apoptosis in TF-
1 cells does not involve the DAXX pathway, but leads to
FADD activation and cleavage of pro-caspase-3 [12]. It
has been demonstrated that overexpression of HSP27 inhibits
DAXX-mediated apoptosis, but not CD95/Fas-induced
FADD/caspase-dependent apoptosis [17]. Indeed, cleavage
of pro-caspase-3 is observed after CD95/Fas treatment of
the TF-1 cells, indicating that CD95/Fas is able to induce
apoptosis without p38 and JNK activation.
Overall, these experiments indicate that HSP27 protects
leukemic cells from VP-16-induced apoptosis through bind-
ing to DAXX and modulation of the activation of the p38/
JNK pathways, whereas CD95/Fas-induced apoptosis is notaffected, either through the upregulation of HSP27 or be-
cause of DAXX-independent signaling through a FADD/
caspase-dependent pathway. This report underscores that in
AML blasts, multiple anti-apoptotic routes are activated
[6,7,28,29,51] and implicates that strategies should be de-
signed in targeting multiple signal transduction pathways in
order to treat this highly malignant disorder.
Recently it has been demonstrated that HSP27 confers
resistance to the proteasome inhibitor Bortezomib/PS-341
[52] and blockade of HSP27 restores sensitivity towards
Bortezomib/PS-341. A similar approach might be relevant
in the treatment of monocytic leukemia.
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